These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?]. Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F; Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811 [TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP; Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702 [TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States. Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950 [TBL] [Abstract][Full Text] [Related]
10. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão. Silva AAMD; Lima-Neto LG; Azevedo CMPES; Costa LMMD; Bragança MLBM; Barros Filho AKD; Wittlin BB; Souza BF; Oliveira BLCA; Carvalho CA; Thomaz EBAF; Simões-Neto EA; Leite Júnior JF; Cosme LMSS; Campos MAG; Queiroz RCS; Costa SS; Carvalho VA; Simões VMF; Alves MTSSBE; Santos AMD Rev Saude Publica; 2020; 54():131. PubMed ID: 33331525 [TBL] [Abstract][Full Text] [Related]
12. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398 [TBL] [Abstract][Full Text] [Related]
14. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201 [TBL] [Abstract][Full Text] [Related]
15. Severe acute respiratory syndrome-coronavirus-2 seroprevalence study in Pimpri-Chinchwad, Maharashtra, India coinciding with falling trend - Do the results suggest imminent herd immunity? Banerjee A; Gaikwad B; Desale A; Jadhav SL; Rathod H; Srivastava K Indian J Public Health; 2021; 65(3):256-260. PubMed ID: 34558487 [TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. Ristić M; Milosavljević B; Vapa S; Marković M; Petrović V PLoS One; 2021; 16(7):e0254516. PubMed ID: 34242377 [TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia. Herlinda O; Bella A; Kusnadi G; Swasthika Nurshadrina D; Thoriq Akbar M; Nida S; Salama N; Ariawan I; Saminarsih D PLoS One; 2021; 16(12):e0261931. PubMed ID: 34941968 [TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France. Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070 [TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19. Zaidi S; Rizwan F; Riaz Q; Siddiqui A; Khawaja S; Imam M; Naz A; Waheed S; Shamsi T J Public Health (Oxf); 2021 Apr; 43(1):3-8. PubMed ID: 32940328 [TBL] [Abstract][Full Text] [Related]
20. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study. Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW; Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]